Quiz|Articles|April 24, 2026

OncLive Weekly News Quiz (4/24/2026): Test Your Knowledge on Key Bladder and Kidney Cancer Updates

Author(s)OncLive Staff
Fact checked by: Chris Ryan

Key Takeaways

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA granted priority review to perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for patients with cisplatin-eligible muscle-invasive bladder cancer based on which key finding from the phase 3 KEYNOTE-B15 trial (NCT04700124)?



Latest CME